Skip to main content

Treatment Clinical Trials for Multiple Myeloma/Plasma Cell Myeloma

Review the multiple myeloma/plasma cell myeloma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-197 of 197

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Status: Active
Location: 2 locations
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Status: Active
Location: See ClinicalTrials.gov
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Status: Active
Location: 4 locations
Dose-escalation Study of Oral CX-4945
Status: Active
Location: See ClinicalTrials.gov
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Status: Active
Location: See ClinicalTrials.gov
Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for the Treatment of Multiple Myeloma in Ultra-Frail Patients
Status: Approved
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Genetically Modified T Cells (UF-KURE-BCMA CAR-T Cells) for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
211At-OKT10-B10 and Fludarabine Alone or in Combination with Cyclophosphamide and Low-Dose TBI before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Elotuzumab and Lenalidomide after Stem Cell Transplant in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Isatuximab with or without Lenalidomide in Treating Patients with High Risk Smoldering Plasma Cell Myeloma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Daratumumab and Hyaluronidase-fihj and Pomalidomide for the Treatment of Relapsed Multiple Myeloma after Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: 11 locations
Selinexor in Combination with Carfilzomib, Daratumumab or Pomalidomide, and Dexamethasone for the Treatment of Patients with Multiple Myeloma Relapsing on Current Therapy
Status: Temporarily Closed to Accrual
Location: 2 locations
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Anti-BCMA Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: University of California San Francisco, San Francisco, California